TBG Therapeutics

TBG Therapeutics is an early-stage biotechnology company being spun out from research at the University of Toronto and NYU Langone Health to develop therapeutics based on engineered zinc finger proteins. The company appears focused on using a machine learning-enabled zinc finger design platform, referred to in the underlying research as ZFDesign, to create DNA-binding proteins for gene regulation and potential in vivo therapeutic applications. Publicly available information indicates that TBG Therapeutics is working broadly on diseases with genetic components rather than disclosing a mature named pipeline. Its technology is positioned as a potential alternative or complement to CRISPR-based approaches, with an emphasis on human-derived zinc finger proteins, transcription factor reprogramming, and gene control. Available evidence suggests the company remains private and preclinical, with limited public corporate disclosure beyond formation records and academic/news coverage.